Introduction
============

The central nervous system (CNS), which is composed of the brain and spinal cord, is a highly integrated and complex network made up principally by neuronal and glial cells. Neuronal cells or neurons as the working unit of the CNS are specialized to transmit information. Glial cells function more in a supportive capacity to surrounding neurons and, nonetheless, as has been increasingly recognized, also actively participate in many functional aspects of the CNS through bi-directional and dynamic interactions ([@B33]; [@B4]; [@B54]). There are several types of glial cells with different embryonic origins ([@B60]). Astrocytes, oligodendrocytes, and neural-glial antigen 2-positive cells are derived from neuro-ectoderm that also gives rise to neurons, whereas microglial cells are myeloid-lineage cells originated from mesoderm that generates cells of the blood and immune system. Therefore, microglial cells are privileged to be the immune-competent cells of the CNS, like macrophages in the systemic immune system, and thus are often referred to as CNS-resident macrophages. Under healthy or steady-state conditions, microglial cells exhibit a distinctive morphology characteristic of high ramification with an extensive network of fine processes stemming from a small cell body and a resting phenotype ([@B69]). Microglial cells can secret neurotrophic factors \[e.g., brain-derived neurotrophic factor (BDNF)\] and, using their phagocytic capability, eliminate excessive or dysfunctional synapses and clear apoptotic developing neurons. In this way, microglial cells support neuronal functions, particularly important processes such as neurogenesis and synaptogenesis during brain development and in the adult brain ([@B56]; [@B77]; [@B44]; [@B106]; [@B45]; [@B32]; [@B54]). In addition, microglial cells act as the sentinel of the CNS and unceasingly patrol the surroundings with their fine processes to monitor environmental changes and provide the first defensive mechanism in response to damage and infection. Microglial cells express a repertoire of the so-called pattern recognition receptors (PRRs), with Toll-like receptors (TLRs), and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) being two example groups. PRRs detect danger-associated molecular patterns (DAMPs) released from host cells due to damage or stress or pathogen-associated molecular patterns (PAMPs) generated by invading pathogens ([@B10]; [@B36]). Upon ligation of PRRs by DAMPs and/or PAMPs, microglial cells become activated and, after retracting their processes and taking on a spherical form, adopt an amoeboid morphology, proliferate and migrate to the site of damage or infection, where they remove damaged cells or pathogens via phagocytosis ([@B22]). Microglial cells can generate proinflammatory mediators that are instrumental in heightening acute immune responses, including chemokines \[e.g., C-X-C motif ligand 2 (CXCL2)\], cytokines \[e.g., interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6\], nitric oxide (NO), and reactive oxygen species (ROS). Activated microglial cells can also assume distinctive and anti-inflammatory phenotypes and produce anti-inflammatory cytokines and neurotrophic factors \[e.g., IL-10, tissue growth factor (TGF)-β and BDNF\] that are important in resolving inflammation and stimulating tissue repair ([@B99]; [@B89]; [@B54]). It is increasingly clear that microglial cells exhibit a high level of heterogeneity in the developing brain and an increase in varied proinflammatory subtypes in the aged, inflamed or neurodegenerative brain ([@B21]; [@B81]).

It is known that numerous DAMPs are released by cells in the CNS as a result of aging, traumatic damage, chronic psychological stress or neurodegenerative diseases, with ATP being one such well-documented example ([@B36]; [@B100]). It is also well-known that DAMPs are released from degenerating neurons in the brain, such as misfolded amyloid β-peptides (Aβ), α-synuclein, and superoxide dismutase 1 ([@B19]). These DAMPs are potent inducers of chronical activation or senescence of microglial cells, leading to elevated generation of pro-inflammatory mediators that alters neuronal functions and induces neurotoxicity, a process often referred to as neuroinflammation ([@B19]; [@B27]; [@B54]). Studies over the past decade have gathered a large body of evidence to support that microglial cells play a key role in mediating neuroinflammation as a significant contributing factor in the progression of aging and a wide spectrum of CNS conditions, including ischemic stroke, traumatic brain damage, Alzheimer's disease (AD), Parkinson's disease (AD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), neuropsychiatric disorders \[e.g., depression, bipolar disorder (BD), and schizophrenia\], autism spectrum disorders (ASD), and neuropathic pain ([@B19]; [@B106]; [@B15]; [@B31]; [@B36]; [@B55]; [@B67]; [@B70]; [@B2]; [@B9]; [@B32]; [@B54]; [@B74]; [@B86]; [@B97]).

Oxidative stress, resulting from excessive ROS generation, impaired antioxidant capacity, or both, is a common and salient feature in aging and the aforementioned CNS diseases. The transient receptor potential melastatin-related 2 (TRPM2) channel is a Ca^2+^-permeable cationic channel with a high sensitivity to oxidative stress or ROS ([@B23]; [@B108]) and is a member of the large transient receptor potential (TRP) superfamily ([@B11]). In the systemic immune system, the TRPM2 channel has been recognized as an important molecular mechanism mediating DAMP/PAMP-induced generation of proinflammatory mediators and innate immune responses ([@B46]; [@B85]). Expression of the TRPM2 channel is widely distributed in the CNS with a high level in microglial cells. In this article, we focus on the TRPM2 channel in microglial cells and its role in neuroinflammation. We start with a brief introduction of the TRPM2 channel activation followed by a summary of the evidence supporting TRPM2 channel expression in microglial cells. We proceed to describe the studies that show an important role of the TRPM2 channel in microglial cell activation and generation of proinflammatory mediators in response to various DAMPs and PAMPs, and also the current understanding regarding the molecular mechanisms responsible for DAMP/PAMP-induced TRPM2 channel activation and the downstream TRPM2-dependent signaling pathways engaged in microglial cell activation and generation of proinflammatory mediators. We also discuss the studies using rodent models that demonstrate the role of the TRPM2 channel in microglial cell activation and neuroinflammation in CNS diseases. Finally, we highlight the gaps in our understanding that require further investigation in order to test whether targeting the TRPM2 channel, a new player in neuroinflammation, could represent a neuroprotective approach to tempering the progression of aging or CNS diseases.

TRPM2 Channel Activation
========================

Up to now, it has been established both functionally and structurally that the TRPM2 channel is a ligand-gated Ca^2+^-permeable cationic channel activated by intracellular ADP-ribose (ADPR), and that ADPR-induced TRPM2 channel activation displays strong dependence of intracellular Ca^2+^ ([Figure 1A](#F1){ref-type="fig"}) ([@B65]; [@B57]; [@B58]; [@B91]; [@B102]; [@B14]; [@B92]; [@B30]; [@B98]; [@B109]). Several ADPR analogs, including ADPR-2′-phosphate, 2′-*O*-acetyl-ADPR and 2′-deoxy-ADPR, have been shown to gate the TRPM2 channel ([Figure 1A](#F1){ref-type="fig"}) ([@B20]; [@B93]; [@B16]). Cyclic ADPR (cADPR), nicotinamide adenine dinucleotide (NAD) and other structurally or metabolically ADPR-related compounds were also reported in earlier studies using whole-cell recording to activate the TRPM2 channel ([@B71]; [@B48]; [@B7]; [@B90]). This notion however has been challenged by more recent studies using the excised inside-out recording to show that application of these compounds to the intracellular face of the TRPM2 channel failed to induce TRPM2 channel activation ([@B92]; [@B93]).

![Direct and indirect mechanisms inducing TRPM2 channel activation. Summary of the major mechanisms that are responsible for direct **(A)** or indirect **(B)** activation of the Ca^2+^-permeable TRPM2 channel on the cell surface that mediates Ca^2+^ influx leading to an increase in intracellular Ca^2+^ concentrations. **(A)** Intracellular Ca^2+^, ADPR and several ADPR analogs binds to and activate the TRPM2 channel alone or in synergy. Warm temperature can also induce TRPM2 channel activation in a yet not well-defined mechanism. The TRPM2 channel inhibitors used in the studies discussed in this review are shown here, and note that none of these inhibitors are TRPM2-specific. **(B)** ROS can potently but indirectly induce TRPM2 channel activation, mainly via PARP-1/PARG-mediated ADPR generation from NAD in the nucleus. ADPR, ADP-ribose; ADPR-2′-P, ADPR-2′-phosphate; 2-APB, 2-aminoethyl diphenylborinate; FFA, flufenamic acid; ROS, reactive oxygen species; NAD, nicotinamide adenine dinucleotide; pADPR, poly(ADPR); PARP1, poly(ADPR)-polymerase 1; PARG, poly(ADPR)-glycohydrolase.](fphar-10-00239-g001){#F1}

It is also known that warm temperature (≥35°C) induces TRPM2 channel activation alone or in synergy with other TRPM2 channel activators ([Figure 1A](#F1){ref-type="fig"}), as shown in pancreatic β-cells and macrophages ([@B90]; [@B42]; [@B43]). In this aspect, recent studies have revealed an important role for the TRPM2 channel in sensory neurons in the peripheral and central nervous systems in detecting non-noxious warmth and regulating body temperature ([@B79]; [@B88]).

As introduced above, TRPM2 channels display high sensitivity to activation under oxidative stress or more specifically exposure to elevated levels of ROS, thus gaining increasing recognition for their role in mediating cellular responses to oxidative stress ([@B41]; [@B61]; [@B87]; [@B46]; [@B68]; [@B51], [@B52]; [@B85]; [@B104]). While some earlier studies suggested that ROS such as H~2~O~2~ may directly activate the TRPM2 channel, it is now widely accepted that ROS-induced TRPM2 channel activation is indirect and depends on mechanisms that promote an increase in intracellular ADPR level ([@B41]). One widely-employed mechanism in many types of mammalian cells is generation of ADPR from NAD by poly(ADPR)-polymerase (PARP), particularly PARP-1, and poly(ADPR)-glycohydrolase (PARG) in the nucleus ([Figure 1B](#F1){ref-type="fig"}). Some evidence exists to suggest that ADPR generation from NAD catalyzed by NADase in the mitochondria also contributes in ROS-induced TRPM2 channel activation ([@B66]).

TRPM2 Channel Expression in Microglial Cells
============================================

Studies examined TRPM2 channel expression in microglial cells at the mRNA, protein and/or functional levels using reverse transcription-polymerase chain reaction (RT-PCR), immunostaining, western blotting, Ca^2+^ imaging and/or patch-clamp current recording ([@B49]; [@B17]; [@B50]; [@B37]; [@B84]). [@B49] were the first to examine TRPM2 channel expression in cultured rat microglial cells. A high level of TRPM2 mRNA expression was detected, and exposure to H~2~O~2~ induced extracellular Ca^2+^ influx, leading to an increase in intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~). Furthermore, application of intracellular ADPR opened a cationic conductance with a linear current-voltage (I-V) relationship and a single channel conductance of ∼65 pS ([@B49]), the key biophysical characteristics of the TRPM2 channels ([@B41]). A recent study shows strong TRPM2 mRNA and protein expression and ADPR-induced cationic currents in cultured mouse microglial cells ([@B37]). Consistently, exposure to H~2~O~2~ (10--300 μM) induced concentration-dependent Ca^2+^ influx and increase in \[Ca^2+^\]~i~ in cultured mouse microglial cells from wild-type (WT) but not TRPM2-knockout (TRPM2-KO) mice ([@B84]). Profiling the TRPM2 mRNA level in numerous human tissues, including the brain and spinal cord, revealed abundant expression and a wide distribution of TRPM2 expression in the CNS ([@B17]). In C13, a human microglial cell line, TRPM2 mRNA transcripts were also readily detected, and exposure to H~2~O~2~ induced a robust increase in \[Ca^2+^\]~i~. Both the mRNA expression level and H~2~O~2~-induced Ca^2+^ responses were reduced in C13 cells after treatment with TRPM2-specific antisense oligomers ([@B17]). Furthermore, application of intracellular ADPR or extracellular H~2~O~2~ elicited cationic currents that exhibited an almost linear I-V relationship and a strong sensitivity to inhibition by flufenamic acid (FFA), a TRPM2 channel inhibitor ([Figure 1A](#F1){ref-type="fig"}). In cultured human microglial cells isolated from surgically resected temporal lobe tissues, exposure to H~2~O~2~ elicited a strong increase in \[Ca^2+^\]~i~ that was inhibited by treatment with clotrimazole ([@B50]), a TRPM2 channel inhibitor ([Figure 1A](#F1){ref-type="fig"}). These studies have gathered compelling evidence to support TRPM2 channel expression in human and rodent microglial cells as a Ca^2+^ influx pathway with a significant role in ROS-induced Ca^2+^ signaling.

Interestingly, an earlier study noted that there were significantly greater H~2~O~2~-induced Ca^2+^ responses and more readily detectable H~2~O~2~-induced currents in cultured rat microglial cells after exposure to H~2~O~2~ or treatment with lipopolysaccharide (LPS), an endotoxin found in the outer membrane of Gram-negative bacteria and a widely-used PAMP to induce immune cell activation via TLR4 activation ([@B49]). TRPM2 mRNA expression was up-regulated in C13 cells after treatment with IL-1β ([@B17]). As we discuss below, exposure to diverse pathological stimuli or conditions can increase TRPM2 channel expression in microglial cells.

TRPM2 Channel in Microglial Cell Activation and Generation of Proinflammatory Mediators
=======================================================================================

An increasing number of studies have, mainly using cultured microglial cells, investigated the role of the TRPM2 channel in microglial cell activation and generation of proinflammatory mediators in response to diverse pathological stimuli. Furthermore, as discussed in detail next, efforts have been made to gain considerable insights into the mechanisms by which the TRPM2 channel is activated by such stimuli and the downstream TRPM2-dependent signaling pathways in microglial cell activation and generation of proinflammatory mediators ([Figure 2](#F2){ref-type="fig"}).

![TRPM2 channel mechanisms mediating microglial cell activation and generation of proinflammatory mediators. Schematic illustration of the current knowledge of the signaling mechanisms by which various danger- or pathogen-associated molecular patterns activate the TRPM2 channel in microglial cells, leading to microglial cell activation and generation of proinflammatory mediators. **(A)** BSO-induced GSH depletion via inhibition of GCL-mediated GSH synthesis results in oxidative stress that activates the TRPM2 channel. TRPM2-mediated Ca^2+^ influx induces activation of p38, ERK, and JNK MAPKs and NF-κB pathways that drive expression of TNF-α and IL-6. **(B)** Exposure to LPC induces TRPM2 channel activation via currently unknown mechanisms and ensuring TRPM2-mediated Ca^2+^ influx activates p38, leading to microglial cell activation. **(C)** Exposure to LPS/IFN-γ induces NOX-mediated ROS generation and TRPM2 channel activation. TRPM2-mediated Ca^2+^ influx activates Ca^2+^-sensitive proline rich tyrosine kinase PYK2 and downstream p38 and JNK, triggering iNOS expression and NO generation. **(D)** Exposure to Aβ42 induces TRPM2 channel activation via PKC/NOX-mediated ROS generation, activation of nuclear PARP-1 and ADPR generation. TRPM2-mediated Ca^2+^ and subsequent activation of PYK2 and MEK/ERK serves as a positive feedback mechanism for further TRPM2 channel activation. TRPM2-mediated Ca^2+^ signaling induces TNF-α expression. **(E)** LPS priming of microglial cells promotes expression of biologically inactive pro-IL-1β via TLR4. Exposure to Aβ42 induces mitochondrial and NOX-mediated ROS generation, activation of nuclear PARP-1, and generation of ADPR which opens the TRPM2 channel. TRPM2-mediated Ca^2+^ influx activates NLRP3 inflammasome and subsequently caspase-1. Caspase-1 converts by cleavage pro-IL-1β into biologically active IL-1β. For the evidence that supports or suggests these TRPM2 channel mechanisms in mediating microglial cell activation and generation of proinflammatory mediators, refer to the studies discussed in detail in the text. BSO, [D,L]{.smallcaps}-buthionine-*S*,*R*-sulfoximine; GSH, glutathione; GCL, glutamatecysteine ligase; ERK, extracellular signal-regulated kinase; JNK, Jun-N-terminal kinase; MAPK, mitogen-activated protein kinase; TNF-α, tumor-necrosis factor-α; IL, interleukin; LPC, lysophosphatidylcholine; Aβ42, amyloid-β peptide 42; LPS, lipopolysaccharide; IFNγ, interferon γ; NOX; NADPH oxidases; NO, nitric oxide; iNOS, inducible NO synthase; PKC, protein kinase C; PARP-1, poly(ADPR) polymerase 1; TLR4; Toll-like receptor 4; NLRP3, nucleotide binding domain-containing leucine-rich repeat protein 3.](fphar-10-00239-g002){#F2}

Generation of TNF-α and IL-6 Resulting From Impaired Antioxidant Capacity
-------------------------------------------------------------------------

Glutathione (GSH) is present as one of the important reducing agents in most mammalian tissues including the CNS that equip cells with a non-enzymatic antioxidant capacity ([@B59]). Glutamatecysteine ligase (or γ-glutamylcysteine synthase) is a rate-limiting step in GSH synthesis and thus [D,L]{.smallcaps}-buthionine-*S*,*R*-sulfoximine (BSO), an inhibitor of glutamatecysteine ligase, can cause depletion of intracellular GSH and cellular oxidative stress. It has been proposed that a reduction in intracellular GSH with aging increases age-related susceptibility to oxidative stress, which is worsened in many neurodegenerative conditions ([@B78]). A previous study investigated the role of the TRPM2 channel in generating neurotoxic proinflammatory mediators in cultured human microglial cells under BSO-induced oxidative stress ([@B50]). Exposure to BSO (1--24 h) induced an exposure duration-dependent increase in \[Ca^2+^\]~i~. Exposure to BSO for 2 h was sufficient to activate mitogen-activated protein kinases (MAPK), p38, extracellular signal-regulated kinase (ERK) and Jun-N-terminal kinase (JNK), and furthermore downstream nuclear factor NF-κB. BSO-induced increase in \[Ca^2+^\]~i~ and activation of MAPK and NF-κB signaling pathways were significantly suppressed by supplementation with GSH or treatment with clotrimazole. Exposure to BSO (0.1, 0.5 and 1 mM) also induced concentration-dependent release of TNF-α and IL-6 from microglial cells, which was reduced by treatment with TRPM2-specific small interference RNA (siRNA) ([@B50]). These results suggest that oxidative stress resulting from GSH depletion activates the TRPM2 channel and TRPM2-mediated Ca^2+^ influx in turn initiates downstream MAPK and NF-kB signaling pathways, leading to generation of TNF-α and IL-6 ([Figure 2A](#F2){ref-type="fig"}). Human neuroblastoma SH-SY5Y cells cultured in the medium conditioned by BSO-treated microglial cells exhibited substantial cell death ([@B50]). Such cell death was significantly attenuated in the conditioned culture medium that was prior depleted of TNF-α and IL-6. Moreover, SH-SY5Y cell death in the conditioned culture medium was strongly suppressed by supplementing microglial cell culture medium with GSH or treating microglial cells with clotrimazole or TRPM2-siRNA ([@B50]). Collectively, these results suggest that TNF-α and IL-6, generated by microglial cells in a TRPM2-dependent manner, under BSO-induced oxidative stress can induce neurotoxicity.

LPC-Induced Microglial Cell Activation
--------------------------------------

It is known that lysophosphatidylcholine (LPC), an inflammatory phospholipid endogenously generated under physiological and various pathological conditions, can induce extracellular Ca^2+^ influx in microglial cells and microglial cell activation ([@B72]; [@B73]). A recent study has investigated the role of the TRPM2 channel in LPC-induced Ca^2+^-signaling and microglial cell activation in cultured mouse microglial cells ([@B37]). Exposure to LPC induced cationic currents as well as an extracellular Ca^2+^-dependent increase in \[Ca^2+^\]~i~. LPC exposure also resulted in phosphorylation of p38 (p-p38), an indicator of microglial cell activation. Consistently, intrathecal injection of LPC enhanced expression of ionized calcium binding adapter molecule 1 (Iba1) and CD11 in spinal microglial cells, suggesting microglial cell activation ([@B37]). Such LPC-induced *in vitro* or *in vivo* effects in microglial cells were largely prevented by TRPM2-KO ([@B37]). These results support a key role for the TRPM2 channel in LPC-induced Ca^2+^ signaling and activation of downstream p38 MAPK signaling pathways, leading to microglial cell activation ([@B37]) ([Figure 2B](#F2){ref-type="fig"}). It remains unclear regarding the mechanisms by which LPC induces TRPM2 channel activation, and the types of proinflammatory mediators that are generated as a result of LPC-induced microglial cell activation. This study has made an interesting observation that the levels of both total and cell surface TRPM2 protein expression was significantly increased in LPC-treated microglial cells but it is not elucidated how such up-regulation of TRPM2 expression and membrane trafficking occurs.

LPS/IFNγ-Induced Activation of iNOS and Generation of NO
--------------------------------------------------------

The TRPM2 channel was shown, in an *in vivo* study discussed below, to play a significant role in mediating spinal microglial cell activation and neuropathic pain ([@B24]). In this study the authors particularly revealed a role for the TRPM2 channel in cultured microglial cells in the activation of inducible NO synthase (iNOS) and generation of NO after exposure to LPS and IFNγ. A subsequent study by the same group investigated the signaling pathways engaged in LPS/IFNγ-induced TRPM2 channel activation and NO generation ([@B62]). LPS/IFNγ exposure evoked extracellular Ca^2+^ influx to increase \[Ca^2+^\]~i~, which was prevented by TRPM2-KO or treatment with miconazole, a TRPM2 channel inhibitor ([Figure 1A](#F1){ref-type="fig"}). Such Ca^2+^ response was also efficiently inhibited by treatment with diphenylene iodonium (DPI) and ML-171, inhibitors of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidases (NOXs). LPS/IFNγ-induced NO generation was also significantly reduced by TRPM2-KO, or by inclusion of 1,2*-bis*(*o*-aminophenoxy)ethane-*N,N,N,N*-tetraacetic acid (BAPTA), a Ca^2+^ chelator, to remove extracellular Ca^2+^. These results support that LPS/IFNγ induce NOX-mediated ROS generation, TRPM2 channel activation and an increase in \[Ca^2+^\]~i,~ leading to NO generation ([Figure 2C](#F2){ref-type="fig"}). Moreover, LPS/IFNγ-induced NO generation was attenuated by treatment with AG17, an inhibitor for Ca^2+^-sensitive proline-rich tyrosine kinase 2 (PYK2), SB203580, a p38 inhibitor, or SP600125, a JNK inhibitor. Inhibition of LPS/IFNγ-induced NO generation by BAPTA, AG17, SB203580 or SP600125 was abolished by TRPM2-KO. LPS/IFNγ-induced NO generation in microglial cells from both WT and TRPM2-KO mice was attenuated by treatment with PD98059, a MEK/ERK inhibitor. Likewise, exposure to LPS/IFNγ induced selective activation of p38 in WT but not TRPM2-KO microglial cells, but indiscriminate activation of ERK in both WT and TRPM2-KO microglial cells. Overall, these results suggest that LPS/IFNγ-induced TRPM2-mediated Ca^2+^ signaling initiates activation of PYK2 and downstream p38/JNK MAPK signaling pathways for activation of iNOS and subsequent NO generation ([Figure 2C](#F2){ref-type="fig"}).

Aβ42-Induced Microglial Cell Activation and Generation of TNF-α
---------------------------------------------------------------

A recent *in vivo* study using the APP/PS1 mouse model of AD, as discussed further below, has disclosed an important role of the TRPM2 channel in Aβ-induced AD pathologies, including microglial cell activation ([@B64]). It is well-established that TNF-α contributes to AD and neurodegenerative diseases via direct interaction with its death receptor on neurons as well as induction of microglial cell activation to generate additional neurotoxic mediators ([@B1]; [@B40]). Our recent study has explored the molecular mechanisms responsible for TRPM2 channel activation and TNF-α generation in cultured mouse microglial cells induced by exposure to Aβ42, one of the amyloid-β peptides of high relevance to AD ([@B83]). Exposure to Aβ42 (30--300 nM) induced a concentration-dependent and extracellular Ca^2+^-dependent increase in \[Ca^2+^\]~i~. Aβ42-induced Ca^2+^ response was strongly suppressed by treatment with 2-APB, a TRPM2 channel inhibitor ([Figure 1](#F1){ref-type="fig"}), or BAPTA-AM as a membrane-permeable and thus intracellular Ca^2+^ chelator, and furthermore by TRPM2-KO. Exposure to Aβ42 induced cellular ROS generation and activation of nuclear PARP-1. Both Aβ42-induced PARP-1 activation and increase in \[Ca^2+^\]~i~ were suppressed by treatment with PJ34, an inhibitor of PARP enzymes including PARP-1. Furthermore, Aβ42-induced ROS generation, PARP-1 activation and Ca^2+^ responses were inhibited by treatment with chelerythrine, a protein kinase C (PKC) inhibitor, GKT137831, a NOX1/4-seletive inhibitor, or Phox-I2, a NOX2 inhibitor as well as the NOX generic inhibitor DPI. These results indicate that Aβ42 activates the TRPM2 channel by inducing PKC/NOX-mediated ROS generation and subsequent PARP-1 activation and generation of ADPR ([Figure 2D](#F2){ref-type="fig"}). Aβ42-induced PARP-1 activation and increase in \[Ca^2+^\]~i~ were also prevented by treatment with PF431396, a PYK2 inhibitor, or U0126, a MEK/ERK inhibitor. Aβ42-induced PARP-1 activation was significantly reduced but incompletely abolished by TRPM2-KO, and the remaining Aβ42-induced PARP-1 activity in TRPM2-KO microglial cells was prevented by treatment with GKT137831 or Phox-I2 and, in striking contrast, not altered by treatment with PF431396 or U0126. Taken together, these results suggest that Aβ42 stimulates PKC/NOX-mediated ROS generation and PARP-1 activation leading to initial TRPM2 channel activation, and that subsequent TRPM2-mediated Ca^2+^ flux and activation of PYK2, MEK/ERK, and PARP-1 serves as a positive feedback mechanism for further TRPM2 channel activation ([Figure 2D](#F2){ref-type="fig"}). Moreover, exposure to Aβ42 induced noticeable morphological changes in microglial cells and an increase in the expression and release of TNF-α. Aβ42-induced morphological changes and TNF-α generation were prevented by TRPM2-KO and, moreover, by pharmacological inhibition of the aforementioned signaling pathways responsible for TRPM2 channel activation ([@B83]).

Aβ42-Induced Activation of NLRP3 Inflammasome and Generation of IL-1β
---------------------------------------------------------------------

The nucleotide binding domain-containing leucine-rich repeat protein 3 (NLRP3) is a member of the NOD family of PRRs in the cytosol. In response to damage or infection, NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain, and procaspase-1, via protein-protein interactions, assemble a multi-protein complex often termed as the NLRP3 inflammasome. NLRP3 inflammasome activation is required to activate caspase-1, which in turn cleaves pro-IL-1β into IL-1β ([@B94]; [@B10]; [@B36]; [@B80]; [@B101]). It was shown that genetic inactivation of the NLRP3 inflammasome in APP/PS1 mice reduced IL-1β generation by microglial cells, leading to improved spatial memory and attenuation of other AD-related pathological phenotypes ([@B26]). In addition, NLRP3 inflammasome inactivation shifted microglial cells toward an anti-inflammatory phenotype that cleared Aβ peptides, thereby resulting in a reduction in amyloid-β deposition ([@B26]). Therefore, neuroinflammation resulting from NLPR3 inflammasome activation and IL-1β generation in microglial cells has emerged as an important factor contributing to AD pathogenesis, inciting an interest in targeting the NLRP3 inflammasome as a therapeutic approach to AD ([@B25]; [@B101]). It is well-known that NLRP3 inflammasome activation and IL-1β generation in immune cells including microglial cells exhibit a striking convergence on ROS generation ([@B94]; [@B80]). A recent pharmacological study has examined the potential role of the TRPM2 channel in Aβ42-induced NLRP3 inflammasome activation and IL-1β generation in LPS-primed microglial cells ([@B5]). Exposure to Aβ42 at a relatively high concentration (10 μM) induced mitochondrial ROS generation and also IL-1β generation, both of which were suppressed by treatment with DPI at a high concentration (20 μM) that presumably targets mitochondrial ROS generation. Aβ42-induced IL-1β generation was inhibited by treatment with VAS2870 or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate, NOX inhibitors, indicating engagement of NOX-meditated ROS generation. In addition, Aβ42-induced IL-1β generation was reduced by treatment with *N*-acetylcysteine, a ROS scavenger, or DPQ, a PARP-1 inhibitor ([@B5]). Exposure to Aβ42 resulted in a Ca^2+^ influx-dependent increase in \[Ca^2+^\]~i~ that was also strongly inhibited by treatment with DPI, VAS2870, DPQ, or BAPTA-AM. Finally, Aβ42-induced caspase-1 activation, as shown by western blotting, was inhibited by treatment with DPQ or BAPTA-AM ([@B5]). These results are consistent with the notion that Aβ42 induces NLRP3 inflammasome activation and IL-1β generation via stimulating mitochondrial and NOX-mediated ROS generation, activation of PARP-1 and the TRPM2 channel, and subsequent TRPM2-mediated Ca^2+^ influx ([Figure 2E](#F2){ref-type="fig"}). However, more and definitive evidence is required to corroborate the proposed role of the TRPM2 channel.

TRPM2 Channel in Neuroinflammation and CNS Pathologies
======================================================

It is clear from the above discussion that studies based on cultured microglial cells support an important role for the TRPM2 channel in microglial cell activation and generation of neurotoxic proinflammatory mediators in response to DAMPs/PAMPs of high relevance to various CNS diseases. As discussed next, there is increasing evidence from *in vivo* studies using rodent models that supports a critical role for the TRPM2 channel in microglial cells in microglial cell activation, generation of proinflammatory mediators and neuroinflammation in the pathogenesis of CNS diseases ([Figure 3](#F3){ref-type="fig"}).

![Contribution of TRPM2 channel-mediated neuroinflammation in CNS pathologies. Summary of the key events in TRPM2-mediated neuroinflammation implicated in various CNS pathologies. Activation of the TRPM2 channel in microglial cells mediates microglial cell activation, generation of proinflammatory mediators and/or neuroinflammation that have been shown to contribute to the pathogenesis of neuropathic pain, brain damage by chronic cerebral hypo-perfusion and neonatal hypoxia-ischemia, and Aβ-induced AD. CNS, central nervous system; Aβ, amyloid β peptides; AD, Alzheimer's disease.](fphar-10-00239-g003){#F3}

Neuropathic Pain
----------------

It is well-recognized that microglial cell activation in the spinal cord, as well as peripheral neuroinflammation, plays a significant role in the development of chronic neuropathic pain ([@B38]; [@B13]; [@B95]). The role of the TRPM2 channel in mediating spinal microglial cell activation and neuropathic pain was explored in a previous study using two mouse models of neuropathic pain induced by partial sciatic nerve ligation (SNL) and spinal nerve transection (SNT), respectively ([@B24]). Both mechanical allodynia and thermal hyperalgesia observed in WT mice during the 2 weeks following SNL were largely absent in TRPM2-KO mice. In the sciatic nerves on the ligation site, the TRPM2 mRNA level was markedly elevated. SNL induced a significant increase in the number of neutrophils and also in generation of CXCL2 in WT mice, both of which were mitigated or completely prevented in TRPM2-KO mice. SNL also resulted in a strong increase in the TRPM2 mRNA expression in dorsal microglial cells and in the intensity of immunoreactivity for both Iba1 and CD11b. Moreover, there was an increase in p-p38 and strong co-localization of p-p38 and CD11b, further indicating microglial cell activation. SNL-induced increase in the intensity of immunoreactivity for Iba1, CD11b nd p-p38, and co-localization of p-p38 and CD11b in spinal microglial cells was largely prevented by TRPM2-KO. Similarly, SNT induced mechanical allodynia, increased intensity of immunoreactivity to CD11b and p-p38 and their co-localization in dorsal microglial cells, all of which were significantly subdued in TRPM2-KO mice. The study further examined the role of the TRPM2 channel in the generation of proinflammatory mediators in cultured microglial cells exposed to LPS/IFNγ. LPS/IFNγ stimulated CXCL2 generation and NO release as well as an increase in the mRNA expression of CXCL2, TNF-α, IL-1β, IL-6, and iNOS. LPS/IFNγ-induced generation of CXCL2 and NO, and increased mRNA expression of CXCL2 and iNOS were significantly lowered by TRPM2-KO ([@B24]). However, the study revealed no significant effect of TRPM2-KO on the mRNA expression of TNF-α, IL-1β and IL-6, indicating engagement of TRPM2-independent mechanisms. These results support the notion that the TRPM2 channel in spinal microglial cells contributes to neuropathic pain by mediating the generation of proinflammatory mediators to aggravate pro-nociceptive inflammatory responses. As discussed above, LPS/IFNγ-induced NO generation depends on TRPM2-mediated Ca^2+^ signaling and activation of downstream PYK2 and MAPK p38 and JNK signaling pathways ([Figure 2C](#F2){ref-type="fig"}).

Alzheimer's Disease
-------------------

Alzheimer's disease is an age-related neurodegenerative disease with increasing prevalence in a rapidly aging society, representing the most common cause of dementia that afflicts tens of millions of older people worldwide. Aβ accumulation is widely thought to be an early and pathogenic event in AD pathogenesis. Oxidative damage is a conspicuous but mechanistically poorly understood feature of AD. As has been recently reviewed ([@B40]), studies have shown wide expression of the TRPM2 channel in the brain and strong evidence for the TRPM2 channel as a nexus from Aβ generation and oxidative damage to AD pathologies via multiple cellular and molecular mechanisms, including microglial cell activation. Microglial cells are known to have a dual role in AD ([@B8]). They provide a protective role by phagocytic clearance of Aβ, but such a beneficial capacity declines with aging and is overwhelmed by excessive toxic aggregates, becoming inefficient. As introduced above, Aβ can induce chronic activation and senescence of microglial cells leading to excessive generation of ROS and numerous neurotoxic proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, which constitutes a critical component of AD pathogenesis. APP/PS1 mice co-express a chimeric mouse/human amyloid precursor protein (APP) with the Swedish mutations (K670N and M671L) and human presenilin 1 (PS1) with deletion of exon 9 ([@B35]). A recent study has examined the role of the TRPM2 channel in Aβ-induced AD pathogenesis using this mouse AD model ([@B64]). As has been well-documented, the APP/PS1 mice exhibit excessive Aβ generation, amyloid deposits and synaptic loss in the hippocampus and cortex, microglial cell activation, and severe impairment in age-related spatial memory. Genetic deletion of TRPM2 expression in APP/PS1 mice, while resulting in no alteration in amyloid deposition, essentially reversed Aβ-induced synaptic loss, microglial cell activation, and memory impairment ([@B64]). These results provide compelling evidence to support a critical role for the TRPM2 channel in Aβ-induced AD-related pathologies. As already discussed above, recent *in vitro* studies reveal an important role of the TRPM2 channel in mediating Aβ42-induced microglial cell activation and generation of TNF-α ([@B83]) and possibly IL-1β ([@B5]).

Brain Damage by Deficient Cerebral Blood Circulation
----------------------------------------------------

The brain is well-known for its vulnerability to damage by deprivation or restriction of oxygen and/or glucose supply that can occur under conditions such as cerebral ischemic stroke, cardiac arrest, chronic cerebral hypo-perfusion, and neonatal hypoxia-ischemia. Oxidative stress, mainly due to increased ROS generation, is a common characteristic of these conditions. An early study demonstrated elevated TRPM2 mRNA expression in rat brains at 1 and 4 weeks after transient middle cerebral artery occlusion (MCAO), a widely-used rodent model of ischemic stroke ([@B17]). A number of recent studies, using various *in vitro* and *in vivo* mouse models of ischemia-reperfusion in conjunction with pharmacological inhibition or genetic deletion of the TRPM2 channel, have supported a critical role of the TRPM2 channel in ischemia-reperfusion brain damage and associated cognitive dysfunction ([@B39]; [@B3]; [@B76], [@B75]; [@B18]; [@B105]). There is also emerging evidence to indicate a role for the TRPM2 channel in mediating brain damage due to hypoxia-ischemia in neonates ([@B29]) and chronic cerebral hypo-perfusion in adults ([@B63]).

Of notice, much of the research in this area has so far been devoted to the TRPM2 channel in mediating neuronal death. Nonetheless, there is increasing evidence to suggest a significant contribution of TRPM2-mediated neuroinflammation. For example, selective deletion of the TRPM2 expression in peripheral immune cells substantially protected infarction and cognitive impairment in mice after transient MCAO and reperfusion ([@B18]). However, the role of the TRPM2 channel in microglial cells in ischemia-reperfusion brain damage largely remains unclear. In the case of neonatal hypoxia-ischemia, a recent study shows that infarction in postnatal day 7 pups, induced by ligating the right common carotid artery and reducing oxygen supply and examined 24 h or 7 days afterward, was considerably attenuated in heterozygous and homozygous TRPM2-KO pups. In addition, WT pups exhibited sensorimotor dysfunction at 7 days post hypoxia-ischemia, and such deficits were less noticeable in heterozygous and homozygous TRPM2-KO pups. In WT pups, the TRPM2 mRNA expression was greater in the damaged hemisphere than the healthy hemisphere. Hypoxia-ischemia induced a massive increase in the number of glial fibrillary acidic protein (GFAP) positive cells and Iba1-positive cells in WT pups, but not in heterozygous and homozygous TRPM2-KO pups. These results suggest that the TRPM2 channel plays an important role in mediating activation of glial cells, including microglial cells, thereby inducing neonatal hypoxic-ischemic brain damage. The role of the TRPM2 channel in microglial cells has been best understood in brain damage by chronic cerebral hypo-perfusion ([@B63]). Mice manifested significant white matter damage and cognitive dysfunction 28 days after introduction of bilateral common carotid artery stenosis (BCAS), a model of chronic cerebral hypo-perfusion. At this time point, there was also a significant increase in the TRPM2 mRNA expression and in the level of IL-1β, TNF-α and IL-6 in the corpus callosum. Such BCAS-induced effects, namely, white matter damage, cognitive dysfunction and increased generation of IL-1β, TNF-α and IL-6, were prevented by TRPM2-KO. There was an increase in the number of GFAP positive cells and Iba-1 positive cells in the corpus callosum at 14 and 28 days after BCAS, but only the number of Iba-1 positive cells was strongly suppressed by TRPM2-KO. The increase in the number of Iba1-positive cells and cognitive dysfunction in BCAS-operated mice was effectively prevented by administration of minocycline, an inhibitor of microglial cell and macrophage activation. Further analysis, using WT and TRPM2-KO mice with bone marrow (BM)-derived cells replaced by WT GFP-labeled BM-derived cells, indicates that the Iba-1 positive cells in white matter mainly are largely microglial cells. Collectively, these results therefore support a critical role for the TRPM2 channel in mediating microglial cell activation and generation of proinflammatory cytokines, IL-1β, TNF-α and IL-6, in the aggravation of cognitive impairment by chronic cerebral hypo-perfusion.

Summary and Perspectives
========================

In summary, the TRPM2 channel is highly expressed in microglial cells and mainly functions as a plasma membrane Ca^2+^-permeable cationic channel with a key role in mediating ROS-induced Ca^2+^ signaling ([Figure 1B](#F1){ref-type="fig"}). In addition, the TRPM2 channel in microglial cells is potently activated by diverse DAMPs and/or PAMPs that induce mitochondrial and/or NOX-mediated ROS generation, activation of PARP-1 and ADPR generation ([Figure 2](#F2){ref-type="fig"}). Studies using rodent models in combination with pharmacological and genetic interventions support a significant role for the TRPM2 channel in microglial cell activation and neuroinflammation in the pathogenesis of various CNS conditions. Currently, this includes neuropathic pain, chronic cerebral hypo-perfusion brain damage, neonatal hypoxia-ischemia and Aβ-induced AD ([Figure 3](#F3){ref-type="fig"}). As mentioned in the introduction, microglial cell-mediated neuroinflammation is a well-recognized factor in the pathogenesis of many other CNS conditions besides the aforementioned conditions. Research has also implicated TRPM2 channel in PD ([@B82]; [@B6]; [@B53]), MS ([@B96]), traumatic brain damage ([@B12]; [@B107]), and neurodevelopmental disorders such as ASD ([@B28]) and depression ([@B103]; [@B34]; [@B110]; [@B47]) as well as ischemic stroke brain damage. Evidently, further research is required to investigate whether the TRPM2 channel in microglial cells in mediating neuroinflammation plays a significant role in these CNS conditions.

As discussed above, recent studies have gained significant insights into the molecular mechanisms by which DAMPs and/or PAMPs induce activation of the TRPM2 channel and generation of diverse proinflammatory mediators that are of strong relevance to various CNS diseases. It is clear from the discussion that the current understanding remains fragmented with better insights in some cases than others ([Figure 2](#F2){ref-type="fig"}). Further research is required to provide a coherent understanding of how the TRPM2 channel is activated in response to distinctive stimuli or under different conditions, leading to activation of downstream Ca^2+^ signaling pathways, and ultimately how such TRPM2-dependent signaling pathways drive microglial cell activation and generation of proinflammatory mediators.

Given the widespread indication of a significant role for the TRPM2 channel in mediating neuroinflammation and CNS diseases, the TRPM2 channel represents an attractive therapeutic target. The TRPM2 channel also plays important roles in a number of physiological processes, such as insulin release from pancreatic β-cells, regulation of temperature sensation, and peripheral immune responses, which may complicate the concept of targeting TRPM2 as a therapeutic strategy. However, TRPM2 channel expression in the CNS is selectively up-regulated by diverse pathological stimuli or diseased conditions. With continual research into TRPM2 modulation and function in specific cell types, future developments may focus on pharmacological agents that can improve the outcome for patients with CNS diseases while sparing the physiological functions of the channel. Targeting the TRPM2 channel in microglial cells, a newly-emerged player in neuroinflammation, represents an interesting a venue of development of promising therapeutics.
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